로그인
보증업체
스포츠중계
스포츠분석
먹튀사이트
지식/노하우
판매의뢰
업체홍보/구인
뉴스
커뮤니티
포토
포인트
보증카지노
보증토토
보증홀덤
스포츠 중계
기타
축구
야구
농구
배구
하키
미식축구
카지노 먹튀
토토 먹튀
먹튀제보
카지노 노하우
토토 노하우
홀덤 노하우
기타 지식/노하우
유용한 사이트
제작판매
제작의뢰
게임
구인
구직
총판
제작업체홍보
실시간뉴스
스포츠뉴스
연예뉴스
IT뉴스
자유게시판
유머★이슈
동영상
연예인
섹시bj
안구정화
출석하기
포인트 랭킹
포인트 마켓
로그인
자동로그인
회원가입
정보찾기
뉴스
더보기
[실시간뉴스]
與 통합 법안 통과에 대전 반발 격화…이장우 "법외 주민투표 강행"(종합)
N
[실시간뉴스]
헌재 "재판소원, 위헌·사법권 독립 침해 주장 헌법상 근거 없어"
N
[IT뉴스]
건설연·국토부, 건설산업 정책간담회...국가전략 R&D 발굴 협력키로
N
[연예뉴스]
미쓰홍 진짜 위기 맞았다..박신혜와 '예삐' 김도현 관계 회복되려나
N
[연예뉴스]
박소영, 결혼 2년만 경사... 시험관 시술 중 자연 임신 [공식]
N
커뮤니티
더보기
[자유게시판]
드디어 금요일이군요
[자유게시판]
오늘 다저스 어떻게 생각하시나요
[자유게시판]
하아 댓노
[자유게시판]
식곤증지립니다요
[자유게시판]
벌써 불금이네요
목록
글쓰기
[IT뉴스]Xcell Therapeutics Hits Upper Limit...Celemics·QuadMedicine ↑[K-Bio Pulse]
온카뱅크관리자
조회:
15
2026-02-13 08:07:30
<div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> <section dmcf-sid="tPbXi7GhO5"> <div contents-hash="6c1cb109b1599279b793d6c13c258733e11870d1eb2b84ae64deaa08f74e6be6" dmcf-pid="FQKZnzHlDZ" dmcf-ptype="general"> <div> This article was released as <strong>Pharm Edaily Premium Content</strong> on February 6, 2026, at 8:00 AM. </div> </div> <p contents-hash="e700bbd0c4a6afa279e40df49b1d2e61b18b0685f1fe25071f9ae508c30cbd19" dmcf-pid="3z1IfHsAIX" dmcf-ptype="general">[Seungkwon Kim, Edaily Reporter] With the South Korean government actively pushing the KOSDAQ toward the "3000p" mark a warm breeze blew through the pharmaceutical and bio sectors. </p> <p contents-hash="e966206ba9bd6886bde500ce8d06b9bd4d9e72e6f311a22a5ff8cc9a5c853255" dmcf-pid="0qtC4XOcwH" dmcf-ptype="general">On this day, the market saw a concentrated influx of buying interest toward "Bio So Bu Jang" (Materials, Parts, and Equipment) companies with specialized technological moats and firms undergoing management transitions. </p> <p contents-hash="a9ac86a635da53a59cbed35bf987d501b16f68187fd5ed40689ab09e0efaa70c" dmcf-pid="pBFh8ZIkwG" dmcf-ptype="general">The key protagonists of the market were XcellTherapeutics, Celemics and QuadMedicine. In particular Xcell Therapeutics which possesses proprietary technology for Cell and Gene Therapy (CGT) media hit the upper price limit leading the sector's momentum. </p> <p contents-hash="578888555d0500cd7f61adb4750e233b0203472854ca14369c5acc8887c1f989" dmcf-pid="Ub3l65CEsY" dmcf-ptype="general">It was followed by Celemics fueled by news of a change in its largest shareholder and QuadMedicine which proved its innovative platform capabilities through a major government project.</p> <p contents-hash="ee727f151465de44f1e11fc3fde9789a46e8a385751450658fe7d5cb4e6dbe91" dmcf-pid="uK0SP1hDDW" dmcf-ptype="general">The explosive rally of Xcell Therapeutics was analyzed as being triggered by the surge in demand for "Chemically Defined Media" (CDM) following regulatory changes in Taiwan.</p> <figure class="figure_frm origin_fig" contents-hash="b9b33b1199343aba3aa438c70acee7d223d37837cb842a4fcaf17936765dfccb" dmcf-pid="79pvQtlwOy" dmcf-ptype="figure"> <p class="link_figure"><img alt="Xcell Therapeutics Stock Price Trend" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202602/13/Edaily/20260213080348380mqek.png" data-org-width="800" dmcf-mid="Z44C4XOcsF" dmcf-mtype="image" height="auto" src="https://img1.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202602/13/Edaily/20260213080348380mqek.png" width="658"></p> <figcaption class="txt_caption default_figure"> Xcell Therapeutics Stock Price Trend </figcaption> </figure> <p contents-hash="7497ece0e832fc4e4b4a64622bb01a51ce6b245a75dac849498e1ee566a42d81" dmcf-pid="z2UTxFSrIT" dmcf-ptype="general"><strong>Xcell Therapeutics: Strategic Shift to Exclusive Contract in Taiwan Drives Market Frenzy</strong></p> <p contents-hash="1ef886f57380355a4b55823f112ddc4e182e983e5a874d53ced09ef3e49f368c" dmcf-pid="qVuyM3vmEv" dmcf-ptype="general">According to KG Zeroin MP Doctor, Xcell Therapeutics closed at 1,912 won up 29.9% from the previous trading day on the KOSDAQ market. The news of its Taiwanese partner transitioning to an exclusive distribution agreement acted as a major catalyst for investor sentiment. </p> <p contents-hash="3fdad8f5f42e865544d47852cfcece1297a3bdc8d41e8966745f756e23e0ee55" dmcf-pid="Bf7WR0TsrS" dmcf-ptype="general">This momentum followed an exclusive report by PharmEDaily on Feb 4, featuring an interview with Yi Ui-il, CEO of Xcell Therapeutics, who predicted double digit growth in Taiwan as the market shifts toward chemically defined media.</p> <p contents-hash="cc37c92a6efec65f4f4a148200c47667938bab577d41e08c794a437955c8874d" dmcf-pid="b6BHJuYCDl" dmcf-ptype="general">Xcell Therapeutics is a specialized bio-equipment firm that develops and produces serum free chemically defined media essential for manufacturing CGTs. The company's proprietary CDM is recognized as a next-generation solution that eliminates the risk of viral infection and quality variance associated with traditional Fetal Bovine Serum (FBS) media.</p> <p contents-hash="0ff819aac9451943a0112037bf3bb5e0c9cb4d43da45bf6e3af240decde8ee10" dmcf-pid="KPbXi7GhIh" dmcf-ptype="general">Since 2024, the company has targeted the Taiwanese market through a partnership with "I" a prominent local bio distributor. In just two years Taiwan emerged as a core market accounting for the largest share of the company’s overseas revenue. </p> <p contents-hash="ba29051e19f1f54cda305a04ab02846ede31ce2c5a4d366dc9fc486df45d0cb7" dmcf-pid="9QKZnzHlsC" dmcf-ptype="general">Partner "I" recently converted its non exclusive contract into an exclusive one and visited Xcell Therapeutics’ headquarters and GMP facilities on Jan 20 to finalize this year’s business plans.</p> <p contents-hash="8e38eb33f729bd983e03e839838ab9c797c630a5a68467f173072ad90492c96a" dmcf-pid="2x95LqXSwI" dmcf-ptype="general">"Taiwan is our core region and is showing the fastest results among our global entry points" said CEO Yi Ui il. "As the local CGT market enters the commercialization stage an environment requiring safe CDM is being established. We expect double-digit revenue growth in Taiwan alone."</p> <p contents-hash="bc3264aa4f29114d5f403fe30cc8dc1769c0e2e108199a82602d5c8cea4d3727" dmcf-pid="VM21oBZvmO" dmcf-ptype="general">The company already received initial orders for its flagship Mesenchymal Stem Cell (MSC) media, CellCor™ MSC CD AOF. Major Taiwanese cell banking firms and multiple CGT developers confirmed the adoption of Xcell’s MSC media.</p> <p contents-hash="561e914126399bf763d11658eb827270f6e65d23706ea999c102212442c0402f" dmcf-pid="fRVtgb5TDs" dmcf-ptype="general">Furthermore the Taiwan Ministry of Health and Welfare (MOHW) implemented a regulation last May requiring evidence of pathogen risk and virus inactivation for all reagents used in cell therapy manufacturing serving as a significant tailwind for the company.</p> <p contents-hash="19bbfb47bc1a9f1a2100bb22d3249f2bf71fe2d71cd8dc070499dab0411488c4" dmcf-pid="4efFaK1ywm" dmcf-ptype="general">Industry experts noted "The technical moat of Xcell Therapeutics is becoming more prominent alongside the localization trend of bio materials. The success in Taiwan proves that the company meets global standards, raising expectations for a valuation re-rating upon its entry into the U.S. market."</p> <figure class="figure_frm origin_fig" contents-hash="59e68a64af785132c01faa1d948dc4963fd87f7ea72e716050aa08260966b7e7" dmcf-pid="8d43N9tWEr" dmcf-ptype="figure"> <p class="link_figure"><img alt="Celemics Stock Trend" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202602/13/Edaily/20260213080349585egnu.png" data-org-width="767" dmcf-mid="5TVOVGmjOt" dmcf-mtype="image" height="auto" src="https://img1.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202602/13/Edaily/20260213080349585egnu.png" width="658"></p> <figcaption class="txt_caption default_figure"> Celemics Stock Trend </figcaption> </figure> <p contents-hash="41740193513521a53b21a4089a235d972e4cb143259a814bc93f27202b4034aa" dmcf-pid="6J80j2FYIw" dmcf-ptype="general"><strong>Celemics: Up 9.5% Following Largest Shareholder Change Announcement</strong></p> <p contents-hash="d090583c49b974a3e5e1c0ed63ac2eafc8d925bd6e3bca34754c12737cb22830" dmcf-pid="PFWEqScnDD" dmcf-ptype="general">Celemics a genomic analysis technology company, closed at 3,920 won, up 9.5% on Feb 5 continuing its upward trend from the previous day’s limit up. The surge reflected market expectations for business diversification following the disclosure of a change in its largest shareholder and a 4.3 billion won third party allocation capital increase.</p> <p contents-hash="f7538d3ed0375de0ca2b718a5284073cad311b3ce9ee9b20a12b8af0c81822c1" dmcf-pid="Q3YDBvkLsE" dmcf-ptype="general">Celemics specializes in "Target Capture Kits" which allow for the efficient screening of specific genomic regions. Its proprietary MSSIC (Massive Separated and Sequence Identified Cloning) technology is a core reagent used in Next-Generation Sequencing (NGS) and can detect COVID-19 variants even from trace samples.</p> <p contents-hash="aff2c92324788491aed1c4082e742cf0e887ea5441ef0003ef94a616051696b2" dmcf-pid="x0GwbTEoDk" dmcf-ptype="general">Under the stock transfer agreement, co CEOs Lee Yong hoon and Kim Hyo gi will transfer approximately 430,000 shares (5.27% of total issued shares) to Park Jong gap at 6,000 won per share. Park will become the largest shareholder with a 5.97% stake, and management control is expected to be transferred during the extraordinary general meeting scheduled for March 5.</p> <p contents-hash="13212de1caf7d9c25c186f77dfe9d3b52582a3fe3bb2b549f71b5cf03c6bbce0" dmcf-pid="yNeBrQztIc" dmcf-ptype="general">The 4.3 billion won raised through the capital increase will be used for operations and business diversification. Additionally, the company plans to issue 5 billion won in Convertible Bonds (CB), allocating 1 billion won to recruitment and market expansion and 400 million won to intangible asset acquisition and overseas branch operations.</p> <p contents-hash="a8ef81ae79cebb96031433215f3e9e04ac492d5b3aca6b87cc086fd1ddaa8d81" dmcf-pid="WjdbmxqFmA" dmcf-ptype="general">While Celemics recorded a revenue of 6.7 billion won and an operating loss of 1.9 billion won in 2024, it has benefited from valuation gains from its 9.8% stake in IMBDx, a liquid biopsy specialist. The market is now watching whether the new leadership and funding will serve as a turning point for the company.</p> <figure class="figure_frm origin_fig" contents-hash="99a63664a3c245c4a36d8b8bcf3d44bb89fada80c3a62929a1518224653f4d97" dmcf-pid="YAJKsMB3rj" dmcf-ptype="figure"> <p class="link_figure"><img alt="QuadMedicine Trend" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202602/13/Edaily/20260213080350876uiqp.png" data-org-width="800" dmcf-mid="185OVGmjm1" dmcf-mtype="image" height="auto" src="https://img3.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202602/13/Edaily/20260213080350876uiqp.png" width="658"></p> <figcaption class="txt_caption default_figure"> QuadMedicine Trend </figcaption> </figure> <p contents-hash="ea988e8dce74e9ae65bf52ddea02ae07b22caa3afb1c5eab2e4a8ace7c65dbdd" dmcf-pid="Gci9ORb0rN" dmcf-ptype="general"><strong>QuadMedicine: Rises 8% on Selection for Phase 2 of K-ARPA-H Project</strong></p> <p contents-hash="8eba509725f04541107c3b71e341512710a67a5b474862d1c50b764b5c49f49f" dmcf-pid="Hkn2IeKpma" dmcf-ptype="general">Medical microneedle platform specialist QuadMedicine closed at 13,530 won, up 8%. The rally was driven by the news that the company was selected for Phase 2 of the "Korean ARPA-H Project" in the health security sector, managed by the K-Health Future Promotion Agency.</p> <p contents-hash="7b5c845400bd414a0b2baf409cf120eb30bc7773f580ed410982041bef41ec39" dmcf-pid="XELVCd9UOg" dmcf-ptype="general">QuadMedicine holds proprietary technology for microneedles that can deliver vaccines or drugs simply by being applied to the skin. The K-ARPA-H project, modeled after the U.S. government’s ambitious R&D program, was launched in 2024 to solve national challenges. </p> <p contents-hash="d3ffd62ab07db4b23c456944204f00017ea1bedbb6d2f2b51b3423ceb610bac1" dmcf-pid="ZOAQyg6bro" dmcf-ptype="general">The QuadMedicine consortium has been conducting research since being selected for the STOREx (Ultra long term Vaccine Storage Technology Development) project last year.</p> <p contents-hash="5b214649d7bfe3ce108a33b1d7b8dfd855f77204536205d1bb586e3e6920010e" dmcf-pid="5IcxWaPKOL" dmcf-ptype="general">In Phase 1, the company applied its Microarray Patch (MAP) material technology to mRNA-LNP (Lipid Nanoparticle) formulations, confirming stability for over six months at refrigerated conditions (2~8°C). This is a breakthrough considering traditional mRNA-LNP vaccines require an ultra-cold chain of -20°C to -70°C, which limits distribution in infrastructure-poor regions.</p> <p contents-hash="0348e005a50f9734dfbd4d7c71cd68497098677f0fde3669db6302b273526adf" dmcf-pid="1CkMYNQ9mn" dmcf-ptype="general">Crucially, Q10-based stability prediction modeling showed that the technology could maintain over 90% drug activity for up to three years. Out of multiple consortia in Phase 1, only two were selected for Phase 2, with QuadMedicine securing one of the spots.</p> <p contents-hash="fd4eac6f38d4409e071d6ad3f04eea03c736ee6af3e580a3d93fc4e4e0de65f9" dmcf-pid="thERGjx2ri" dmcf-ptype="general">In Phase 2, QuadMedicine aims to secure long-term storage data of up to five years for its MAP-applied mRNA-LNP prototypes. The company has already established GMP-certified facilities and an automated manufacturing system. </p> <p contents-hash="e585df8dda3ed916228d58c5f3886584673dcade5ab651bea1e2707c85163b71" dmcf-pid="FlDeHAMVOJ" dmcf-ptype="general">Last year it gained international attention as a next-generation vaccine delivery platform after being invited to the WHO Measles Rubella Microneedle meeting.</p> <p contents-hash="5bc28deea2d2449853dc52a3713206f5f107040d3a5cc2506f784da6d0025efa" dmcf-pid="3SwdXcRfEd" dmcf-ptype="general">"This selection proves that microneedle technology is a core material technology that can drastically improve storage stability, a prerequisite for next generation vaccines." said a QuadMedicine official. "We will contribute to national vaccine sovereignty and strengthen our technological competitiveness in the global vaccine market."</p> <p contents-hash="ddec155ec95496a7a1b6f3903e3d16d350efe2809974f0fd132cb1af3a0ba8cc" dmcf-pid="0vrJZke4me" dmcf-ptype="general">김승권 (peace@edaily.co.kr) </p> </section> </div> <p class="" data-translation="true">Copyright © 이데일리. 무단전재 및 재배포 금지.</p>
댓글등록
댓글 총
0
개
맨위로
이번주
포인트
랭킹
매주 일요일 밤 0시에 랭킹을 초기화합니다.
1
4,000
상품권
2
3,000
상품권
3
2,000
상품권
업체홍보/구인
더보기
[구인]
유투브 BJ 구인중이자나!완전 럭키비키자나!
[구인]
에카벳에서 최대 조건으로 부본사 및 회원님들 모집합니다
[구인]
카지노 1번 총판 코드 내립니다.
[구인]
어느날 부본사 총판 파트너 모집합니다.
[구인]
고액전용 카지노 / 헬렌카지노 파트너 개인 팀 단위 모집중 최고우대
지식/노하우
더보기
[카지노 노하우]
혜택 트렌드 변화 위험성 다시 가늠해 보기
[카지노 노하우]
호기심이 부른 화 종목 선택의 중요성
[카지노 노하우]
카지노 블랙잭 카드 조합으로 히트와 스탠드를 결정하는 방법
[카지노 노하우]
흥부가 놀부될때까지 7
[카지노 노하우]
5월 마틴하면서 느낀점
판매의뢰
더보기
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
포토
더보기
채팅하기